Institutional investors hold a majority ownership of BIIB through the 91.36% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended September 2017, these large investors purchased a net $797.4 thousand shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 1.7 Million shares of Biogen
FIDELITY MANAGEMENT & RESEARCH C... Bought 1.0 Million shares of Biogen
COLUMBIA MANAGEMENT INVESTMENT A... Bought 597.3 Thousand shares of Biogen